The Adderall shortage, announced by the FDA in October 2022, has left millions of ADHD patients struggling to access their vital medication due to increased demand and limited production quotas. Former pharmaceutical sales rep Cale Hlavac sheds light on the root causes, citing stagnant production quotas and rising patient numbers. Despite efforts by drug manufacturers to increase production, the shortage persists, leading to price hikes and challenges for patients like Kyrsten Beaver. Addressing this shortage is crucial for ensuring access to essential ADHD medications and supporting those reliant on them for daily functioning. Seeking support from counseling services and organizations like the Attention Deficit Disorder Association can offer guidance and assistance during these challenging times.